BioSpace News Archive

Verastem, Inc. today announced the grant of stock options to six new employees to purchase an aggregate of 193,980 shares of Verastem Oncology’s common stock and 50,000 restricted stock units (RSUs) to one new employee.

PolarityTE, Inc. (Nasdaq: PTE) announced that the Company will be presenting on its SkinTE technology and clinical outcomes at the 18th annual DFCon Diabetic Foot Global Conference on Thursday, October 11, 2018 in Houston, TX.

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a webcast and conference call from the 23rd International Annual Congress of the World Muscle Society, on Friday, October 5, 2018 at 8:30 am ET

Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that seven studies have been selected for poster presentations at the annual symposium of the North American Neuroendocrine Tumor Society (NANETS) taking place in Seattle, Washington, Oct. 4-6, 2018.

Mark October 17th on the calendar. This is the day that Prime Minister Justin Trudeau of Canada will sign a piece of legislation into law that fully legalizes recreational cannabis.

Each October, INC Magazine chooses leading women pioneers, entrepreneurs and innovators to profile in its annual Women Entrepreneurs issue.

Anixa Biosciences, Inc. today announced that it will present data from its ongoing studies utilizing Cchek™, Anixa’s artificial intelligence (AI) driven early cancer detection technology, at the 30th Anniversary AACR Special Conference – Convergence: Artificial Intelligence, Big Data and Prediction in Cancer.

With the legalization of recreational cannabis coming to Canada in just over one week, Tweed, Uber, and MADD Canada are launching a national awareness campaign focused on informing Canadians on the risks of driving high.

Today SOFIE, an emerging theranostics company focused on Positron Emission Tomography (PET) tracers and radiopharmaceutical-based therapeutics, PET scanners, and radiochemistry systems, announces that the National Institutes of Health (NIH) has awarded the company three grants totaling $5M

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced new positive interim data from ASPIRO, the Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM)